No single blood test, scan, or biopsy can confirm polymyalgia rheumatica (PMR). Diagnosis relies on a combination of clinical features, elevated inflammatory markers, imaging when needed, and the systematic exclusion of conditions that produce similar symptoms. The process can be straightforward when all the classic signs line up, but it gets trickier than many patients expect, partly because so many other diseases in older adults look almost identical to PMR at first glance.
What Doctors Look For First
PMR has a recognizable clinical profile: new bilateral aching and stiffness in the shoulders and often the hips, worse in the morning, in someone over 50 (and usually over 65). Morning stiffness lasting more than 45 minutes is a hallmark. Symptoms tend to come on fairly quickly, developing over days to a few weeks rather than gradually worsening over months. Many people also experience fatigue, low-grade fever, unintentional weight loss, or a general feeling of being unwell.
Early attempts to standardize these observations date back decades. A 1979 British collaborative study across 11 rheumatology units evaluated 236 patients with clear-cut PMR and identified seven criteria that best distinguished the condition from its mimics: bilateral shoulder pain or stiffness, illness onset of less than two weeks, an initial ESR above 40 mm/h, morning stiffness exceeding one hour, age 65 or older, depression or weight loss, and bilateral upper-arm tenderness. Having three or more of those features was considered probable PMR.1PubMed. An evaluation of criteria for polymyalgia rheumatica
In 2012, the European League Against Rheumatism and the American College of Rheumatology jointly published provisional classification criteria that formalized the process into a scoring algorithm. A patient 50 or older with new bilateral shoulder aching and abnormal inflammatory markers gets scored on features like morning stiffness duration, hip pain or limited range of motion, absence of other joint involvement, and absence of rheumatoid factor and anti-CCP antibodies. A score of 4 or higher had about 68% sensitivity and 78% specificity for distinguishing PMR from other conditions. The specificity jumped to 88% when the comparison group was limited to shoulder conditions, but dropped to 65% against rheumatoid arthritis, which is the hardest mimic to separate out.2PubMed. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative Those numbers tell you something important: these criteria are useful but imperfect, especially when the question is “PMR or rheumatoid arthritis?”
Blood Tests and What They Actually Tell You
The two inflammatory markers doctors rely on most are the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Both measure different aspects of inflammation in the body. In classic PMR, one or both are elevated, often substantially. But “classic” is a generous word for a disease that regularly breaks its own rules.
A prospective study of 177 PMR patients found that about 6% had a normal ESR at diagnosis. However, CRP was normal in only about 1% of those same patients. Nine out of ten patients with a normal ESR still had an elevated CRP, meaning that checking both markers catches more cases than relying on ESR alone.3Seminars in Arthritis and Rheumatism. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: A prospective follow-up study Another study found ESR was elevated above 30 mm/h in all patients before treatment, while CRP was raised in 49 out of 55 cases.4PubMed. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up
The practical takeaway: a normal ESR does not rule out PMR, though it makes the diagnosis less likely. CRP is more consistently elevated at the time of diagnosis and is a more sensitive indicator of current disease activity. ESR, on the other hand, turns out to be a better predictor of future relapses. In the 177-patient study, an ESR above 40 mm/h and CRP above a certain threshold at diagnosis independently predicted relapse, but the relapse risk tied to ESR was roughly twice that tied to CRP.3Seminars in Arthritis and Rheumatism. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: A prospective follow-up study So the two markers serve slightly different purposes in the diagnostic and monitoring process.
Doctors also check other blood work, not to confirm PMR directly, but to rule out alternatives. A complete blood count, kidney and liver function tests, thyroid function, and protein electrophoresis help screen for infections, cancers, and metabolic conditions. Rheumatoid factor and anti-CCP antibodies are especially useful in distinguishing PMR from elderly-onset rheumatoid arthritis (more on that below).
The Role of Ultrasound
Imaging is not required to diagnose PMR in every patient, but ultrasound has become an increasingly valuable tool, especially when the clinical picture is ambiguous. The 2012 classification criteria include an optional ultrasound component: when added, the scoring threshold changes and overall diagnostic accuracy improves modestly, with sensitivity around 66% and specificity around 81%.5PubMed. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative
What ultrasound looks for in PMR is fluid around specific structures, particularly the subacromial-subdeltoid bursae in the shoulders and the trochanteric bursae in the hips. A systematic review of imaging studies found that subacromial-subdeltoid bursitis on ultrasound had a sensitivity of about 80% and specificity of 68%. When the finding was bilateral, specificity climbed to 89%, though sensitivity dropped to 66%.6RMD Open. Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review Bilaterality matters because rotator cuff problems and other mechanical shoulder issues tend to be one-sided or at least asymmetric.
A more recent study refined this further, looking specifically at the thickness of the fluid in the subacromial-subdeltoid bursa. Patients with PMR had an average bursal thickness of about 6.9 mm compared with 2.3 mm in patients with rotator cuff tendinopathy. Using a cutoff of 3 mm of bilateral bursal thickening yielded a specificity of over 96% and sensitivity of 84% for distinguishing PMR from rotator cuff disease.7PubMed. Ultrasound-detected bilateral subacromial-subdeltoid bursitis exceeding 3 mm differentiates polymyalgia rheumatica from rotator cuff tendinopathy: a cross-sectional observational study This kind of detailed measurement may become a more standard part of the diagnostic workup, particularly when the question is whether the shoulder pain is inflammatory or mechanical.
The Corticosteroid Response
One of the most distinctive features of PMR is how dramatically and quickly it responds to low-dose corticosteroids, typically prednisone at 12.5 to 25 mg per day. Many patients feel remarkably better within a few days. This brisk response has traditionally been considered supportive of the diagnosis, and some older clinical criteria explicitly included it. If a patient’s symptoms do not improve substantially within one to three weeks of starting corticosteroids, the diagnosis of PMR should be questioned.
This “therapeutic trial” is genuinely useful, but it has limits. Some other inflammatory conditions also improve on prednisone, including rheumatoid arthritis, certain infections, and even some cancers with paraneoplastic inflammation. A dramatic response makes PMR more likely, but it does not confirm it with certainty. Conversely, an incomplete response does not automatically rule PMR out; the dose may be too low, or the patient may have overlapping conditions complicating the picture.
Conditions That Look Like PMR
A large part of diagnosing PMR is making sure it is not something else. The list of conditions that can mimic it is long enough to keep rheumatologists busy, and one primary care cohort study highlighted just how confusing the overlap can be. In that study, the most frequently confused disease was elderly-onset rheumatoid arthritis, followed by late-onset spondyloarthritis and crystal deposition disease. Perhaps most striking, nearly half of the general practitioners in one subgroup were not even aware PMR existed as a diagnosis.8PubMed Central. Diagnosis of polymyalgia rheumatica in primary health care: favoring and confounding factors – a cohort study
Elderly-Onset Rheumatoid Arthritis
The hardest differential diagnosis in PMR is distinguishing it from rheumatoid arthritis that begins in older adults. Both cause morning stiffness, joint pain, and elevated inflammatory markers. The shoulder-predominant, symmetric pattern of elderly-onset RA can be virtually indistinguishable from PMR at the first visit.9PubMed Central. Elderly-onset rheumatoid arthritis vs. polymyalgia rheumatica: Differences in pathogenesis
Anti-CCP antibodies are the most helpful lab test for separating the two. One study found that 65% of elderly-onset RA patients had anti-CCP antibodies, while none of the PMR patients or healthy older control subjects tested positive.10PubMed. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica A positive anti-CCP test in someone with PMR-like symptoms is a strong signal that RA is more likely. A negative result, though, does not rule out RA entirely, since roughly a third of RA patients are anti-CCP negative.
Cancer Mimicking PMR
Malignancy can produce PMR-like symptoms through paraneoplastic inflammation. A case report described a man in his late 70s with bilateral shoulder and hip girdle pain, morning stiffness, and significant weight loss. PMR was initially suspected, but the weight loss prompted cancer screening, which revealed metastatic melanoma presenting with paraneoplastic dermatomyositis.11PubMed. Metastatic melanoma presenting with paraneoplastic dermatomyositis mimicking polymyalgia rheumatica
How common is occult cancer in people presenting with PMR-like symptoms? A study of 118 patients who underwent CT scanning as part of their PMR workup found nine cancers, a rate about four and a half times higher than expected in the general population. Kidney cancer accounted for four of those nine cases, with an even more dramatically elevated incidence. In 80% of patients with cancer, the PMR-like symptoms resolved during cancer treatment, confirming the paraneoplastic mechanism.12PubMed Central. The frequency of occult solid malignancy in patients with polymyalgia rheumatica-like symptoms Red flags that should prompt cancer screening include unexplained weight loss, poor or absent response to corticosteroids, and atypical symptom patterns.
The Giant Cell Arteritis Overlap
PMR and giant cell arteritis (GCA) are closely related conditions that frequently coexist. In patients diagnosed with biopsy-proven GCA, PMR symptoms are present in up to half of cases.13PubMed. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions Going the other direction, a meta-analysis estimated that about 22% of patients diagnosed with PMR have concurrent GCA at the time of their PMR diagnosis, while roughly 42% of GCA patients also have PMR.14Seminars in Arthritis and Rheumatism. Concurrent baseline diagnosis of giant cell arteritis and polymyalgia rheumatica – A systematic review and meta-analysis
This matters for diagnosis because GCA can cause serious complications, including permanent vision loss, if not treated with higher corticosteroid doses than are used for PMR alone. Doctors diagnosing PMR should ask about and watch for GCA symptoms: new headaches, scalp tenderness, jaw pain with chewing, and visual disturbances. PMR can also be the presenting feature in patients who later develop full-blown cranial GCA, so the connection is not just a one-time consideration at diagnosis but something to monitor over time.
PET/CT Scanning for Hidden Vasculitis
When PMR symptoms persist despite treatment or present with unusual features, PET/CT scanning can identify inflammation in large blood vessels that would otherwise go undetected. A study of 84 patients with persistent PMR found that about 61% had a positive PET/CT scan for large vessel vasculitis. The strongest predictors of a positive scan were bilateral diffuse lower limb pain, pelvic girdle pain, and inflammatory low back pain.15Seminars in Arthritis and Rheumatism. Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica Discovering this vascular inflammation changes treatment, often requiring higher steroid doses or additional immunosuppression.16Revista Española de Medicina Nuclear e Imagen Molecular. 18F-FDG PET/CT for the detection of large vessel vasculitis in patients with polymyalgia rheumatica
PET/CT is not a routine part of PMR diagnosis. It is expensive, involves radiation exposure, and is most useful in a specific subset of patients: those whose symptoms do not behave the way straightforward PMR should. Think of it as a next-level tool for cases where the initial diagnosis needs revisiting or where the scope of the disease needs clearer definition.
When PMR Does Not Look Like PMR
Although the textbook picture of PMR focuses on shoulders and hips, a surprisingly large proportion of patients develop symptoms below the elbows and knees. A prospective study of 177 patients found that 45% had distal musculoskeletal manifestations during their disease course, including peripheral arthritis in 25%, carpal tunnel syndrome in 14%, and pitting edema of the hands or feet in 12%.17Arthritis & Rheumatism. Distal musculoskeletal manifestations in polymyalgia rheumatica: A prospective followup study A smaller study found even higher rates, with about half of patients showing distal symptoms. The joints most commonly affected were the wrists, knuckles, and knees. These distal manifestations responded well to corticosteroids and did not lead to joint erosions or progression to rheumatoid arthritis.18Journal of Clinical Rheumatology. Peripheral Musculoskeletal Manifestations in Polymyalgia Rheumatica
These atypical presentations can make initial diagnosis harder. Pitting edema in the hands might suggest heart failure or kidney disease. Peripheral joint swelling can point toward RA. About a third of distal episodes in the prospective study occurred as isolated relapses without the classic proximal symptoms, meaning the connection to PMR was not immediately obvious. Awareness that PMR can extend beyond the shoulders and hips helps prevent misdiagnosis in these less typical cases.
Monitoring Disease Activity After Diagnosis
Diagnosing PMR is not a one-time event. Because the condition waxes and wanes over months to years while patients taper corticosteroids, doctors need reliable ways to detect flares. Blood markers are part of this, but during relapses, ESR was normal in about 48% of cases and CRP in about 56%, making them unreliable as sole indicators of active disease.4PubMed. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up
The PMR Activity Score (PMR-AS) was developed to fill this gap. It combines CRP levels, patient-reported pain, physician assessment, morning stiffness duration, and the ability to raise the arms. A validation study found it performed well for identifying active disease, with 87% sensitivity and 87% specificity at the optimal cutoff score.19Seminars in Arthritis and Rheumatism. Validation of the polymyalgia rheumatica-activity score: A prospective cohort study For detecting flares specifically, a slightly different threshold showed 97% sensitivity and 91% specificity, and tracking the change in score over time performed even better, with near-perfect agreement with clinical flare diagnosis.20PubMed. Performance of the polymyalgia rheumatica activity score for diagnosing disease flares If your rheumatologist asks you to rate your pain and time your morning stiffness at follow-up visits, this scoring system is likely why.
Emerging Biomarkers
The biggest frustration with current PMR diagnosis is that no blood marker is specific to the disease. ESR and CRP tell you inflammation is present, but they cannot tell you why. Researchers have been looking for proteins that could serve as more targeted diagnostics. A case-control study identified three serum proteins with strong diagnostic performance for PMR: the chemokine CXCL9, the cytokine IL-6, and IL-1 receptor antagonist. When comparing untreated PMR patients with healthy controls, IL-6 performed best, with an area under the curve of 0.97. Even when the comparison was against RA patients, the toughest diagnostic challenge, IL-6 still achieved an area under the curve of 0.92.21Frontiers in Immunology. Serum protein biomarkers for polymyalgia rheumatica: a case-control study These numbers are promising, but the research is still early-stage. None of these tests are available in routine clinical practice yet, and they need validation in larger, more diverse populations before they could change how PMR is diagnosed day to day.
Genetic research, meanwhile, has confirmed associations between PMR and certain immune-system gene variants, particularly in the HLA-DRB1 region. A genome-wide meta-analysis identified five significant genetic loci, including three that had not been previously reported.22Rheumatology. Modifiable risk factors and inflammation-related proteins in polymyalgia rheumatica: genome-wide meta-analysis and Mendelian randomization However, the genetic associations with PMR vary across populations and are not strong enough to serve as diagnostic tools.23Seminars in Arthritis and Rheumatism. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica Genetic testing plays no role in the current diagnostic process, but understanding the underlying biology could eventually lead to more specific blood tests.